VEGFR2/CD309 Protein (glycosylated, Monomer, Soluble)

Produktnummer ABIN1589571

Produktdetails

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Protein-Typ: Recombinant

Biologische Aktivität: Active

Proteineigenschaft: glycosylated, Monomer, Soluble

Spezies: Maus

Quelle: Insektenzellen

Verwendungszweck: VEGFR-2/Flk-1 (native), soluble

Sequenz: ASVGLTGDFL HPPKLSTQKD ILTILANTTL QITCRGQRDL DWLWPNAQRD SEERVLVTEC GGGDSIFCKT LTIPRVVGND TGAYKCSYRD VDIASTVYVY VRDYRSPFIA SVSDQHGIVY ITENKNKTVV IPCRGSISNL NVSLCARYPE KRFVPDGNRI SWDSEIGFTL PSYMISYAGM VFCEAKINDE TYQSIMYIVV VVGYRIYDVI LSPPHEIELS AGEKLVLNCT ARTELNVGLD FTWHSPPSKS HHKKIVNRDV KPFPGTVAKM FLSTLTIESV TKSDQGEYTC VASSGRMIKR NRTFVRVHTK PFIAFGSGMK SLVEATVGSQ VRIPVKYLSY PAPDIKWYRN GRPIESNYTM IVGDELTIME VTERDAGNYT VILTNPISME KQSHMVSLVV NVPPQIGEKA LISPMDSYQY GTMQTLTCTV YANPPLHHIQ WYWQLEEACS YRPGQTSPYA CKEWRHVEDF QGGNKIEVTK NQYALIEGKN KTVSTLVIQA ANVSALYKCE AINKAGRGER VISFHVIRGP EITVQPAAQP TEQESVSLLC TADRNTFENL TWYKLGSQAT SVHMGESLTP VCKNLDALWK LNGTMFSNST NDILIVAFQN ASLQDQGDYV CSAQDKKTKK RHCLVKQLII LGMEASLGDR IAMP

Produktmerkmale: Length (aa):654

Reinheit: > 95 % by SDS-PAGE

Anwendungsinformationen

Applikationshinweise: Measured by its ability to inhibit the VEGF165-induced proliferation in human umbilical vein endothelial (HUVE) cells.

Kommentare:

Soluble Receptors

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: The lyophilized mouse sFlk-1 is soluble in water and most aqueous buffers, it should be reconstituted in water or PBS to a concentration of not lower than 100 μg/mL.

Buffer: 25 mM MES, 100 mM NaCl, pH 5.5

Lagerung: 4 °C,-20 °C,-80 °C

Informationen zur Lagerung: The material is stable for greater than six months at -20° C to -70° C. After the first thawing it is recommended to aliquote the material, because repeated freeze-thaw cycles will decrease the activity. Store at 4°C not longer than 2 days.

Haltbarkeit: 6 months

Antigendetails

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Andere Bezeichnung: VEGFR-2/Flk-1 (VEGFR2 Produkte)

Hintergrund: Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not to our knowledge been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR-2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels, modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema. Recombinant human esKDR generated by alternative splicing consist of the first 6 Ig-like loops followed by the unique C-terminal end: GMEASLGDRIAMP.
Synonyms: soluble vascular endothelial growth factor receptor-2, Kdr, Flk1, Ly73, Flk-1, VEGF receptor 2, VEGFR-2, sVEGFR-2

Molekulargewicht: 105 kDa

Gen-ID: 16542

UniProt: P35918

Pathways: RTK Signalweg, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling